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Abstract
For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing
patient’s data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and
patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks
(ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients
with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known.
This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data.
Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel
combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that
can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/
genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new
disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe.
Rare Diseases (RD) are individually rare but collectively a
common health issue. Around 80% of RD are estimated to
have a genetic cause [1]. The time to a genetic diagnosis
however often takes several years and initial clinical diag-
noses are incorrect in up to 40% of families [2]. Around
50% of patients with a RD remain undiagnosed even in
advanced expert clinical settings where whole exome
sequencing (WES) is applied routinely as a diagnostic
approach. Depending on the exact diagnostic setting, the
inclusion criteria and the type of RD, the diagnostic yield
from WES ranges between 15 and 51% of cases [3, 4].
At least two scenarios allow boosting the current yield of
WES. Firstly, there is a value in re-analysing WES data
regularly [5] and on massive scale [6], but not every RD
expert has access to tools enabling this systematically.
Secondly, it is clear that moving beyond the exome can
provide additional benefits [7, 8].
Solve-RD aims to solve a large number of unsolved RD,
for which a molecular cause is not yet known, by imple-
menting both strategies mentioned above. To this end,
Solve-RD applies innovative ways to effectively organise
expertise and data.
Cohorts
To structure its work Solve-RD has defined four types of
cohorts. Cohort 1, “Unsolved Cases”, comprises cases with
an inconclusive WES or whole genome sequencing (WGS)
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from any partnering or associated ERN center. These data
undergo a comprehensive re-analysis effort. Cohort 2,
“Specific ERN Cohorts”, represent disease group specific
ERN cohorts that are analysed by newly applied tailored
-omics approaches. Cohort 3, “Ultra-Rare Rare Diseases”,
includes (groups of) patients with unique phenotypes
identified (and matched) by RD experts from all ERN
participants. For the diseases included in Cohort 4, “The
Unsolvables”, all relevant -omics methodologies will be
used to solve highly recognisable, clinically well-defined
disease entities for which the disease cause has not been
found yet despite considerable previous research investi-
gations including WES and WGS (Table 1).
In total, Solve-RD is targeting to re-analyse >19,000
datasets for cohort 1, sequence ~3500 short- and long-read
WGS for cohorts 2, 3, and 4 and add >3500 additional
-omics experiments including RNA sequencing, epige-
nomics, metabolomics, Deep-WES, and deep molecular
phenotyping. Data collected and produced in Solve-RD
shall be shared via the European Genome-Phenome Archive
(EGA) and the RD-Connect Genome-Phenome Analysis
Platform (GPAP) to allow controlled access by other RD
initiatives and scientists.
Organisation of data
The Solve-RD strategy relies on the availability of
large amounts of good quality, standardised genomic and
phenotypic data and metadata from undiagnosed RD
Table 1 Examples for the specific ERN cohorts and the unsolvables.
Cohort Rationale
Cohort 2: Long-read whole genome sequencing (LR-WGS)
X-linked spinal and bulbar muscular atrophy
(SBMA)
Suspected expansions of repeat disorder or other hidden structural variants (SV)
Hereditary ataxia Suspected expansions of repeat disorder or other hidden SVs
Cohort 2: Genomics and Epigenomics
Unexplained Intellectual Disability (ID): patient-
parent trios
De novo mutation prioritisation very powerful filter for de novo methylation changes
Diffuse gastric cancer Hypermethylation of cancer gene promoter known disease mechanism
Rare pheochromocytomas and paragangliomas Hypermethylation of cancer gene promoter known disease mechanism
Cohort 4
Unsolved syndromes available via ERN ITHACA Aicardi syndrome, Gomez–Lopez Hernandes syndrome, Hallermann–Streiff syndrome are
clinically well-defined entities and have been studied by WES and WGS globally and
remain unsolved
Fig. 1 Solve-RD data infrastructure. Key components of the Solve-RD infrastructure for multi-omics data analysis, illustrating main use and data
available.
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patients and their relatives. Solve-RD follows a centralised
approach, to enable all envisioned analyses. Data sharing in
Solve-RD is regulated by policy documents, available on
the project’s website. To overcome the technical challenge
of centralising large amounts of data, Solve-RD leverages
existing infrastructures such as EGA, GPAP, and comput-
ing clusters from project partners (Fig. 1). In addition,
Solve-RD is developing a cloud-based computing cluster
for collaborative analysis and methods testing (the Solve-
RD Sandbox) and a central database to control and view all
the project’s data and metadata (RD3; rare disease data
about data) using the MOLGENIS open source data plat-
form [9]. Clinical data and pedigree structure for all parti-
cipating individuals is collated through standard terms and
ontologies such as HPO, ORDO, and OMIM using GPAP-
PhenoStore. To share data within the project and
beyond, Solve-RD is an early adopter of the recently
GA4GH-approved (Global Alliance for Genomics and
Health, https://www.ga4gh.org) PhenoPackets standard to
enable exchange of phenotypic and family information [10].
For each individual, WES and/or WGS data are sub-
mitted to GPAP in FASTQ, BAM, or CRAM format. The
sequencing data are processed through a standard pipeline
based on GATK (Genomic Analysis Toolkit variant calling
software) best practices [11, 12]. After that, PhenoPackets,
PED files (for pedigrees), raw data (FASTQ), alignments
(BAM) and genetic variants (gVCF) are transferred to the
EGA, where they are archived and made available to the
consortium (and later on to the broader RD community) for
further analysis. Furthermore, Solve-RD data are connected
to MatchMaker Exchange via GPAP.
To reach the ambitious goal to collect 19,000 unsolved
WES/WGS, Solve-RD has defined several deadlines to
submit data to the project. After each deadline, all data are
processed and released as a data freeze, which is amenable
to corrections via patches. The first data freeze, released in
early 2020, includes data from 8,393 individuals.
In parallel to the collection of existing data for cohort 1,
new omics data are being generated for cohorts 2, 3, and 4.
A common data workflow has been established for all these
data types (Fig. 1). The data collated and generated by
Solve-RD constitutes a unique collection that will be
valuable beyond the project, and the consortium is com-
mitted to make it FAIR under controlled access, through the
EGA and GPAP.
Organisation of expertise
Solve-RD works on the interphase of many disciplines
relevant to solving the unsolved RD. Central to the RD field
are clinical geneticists and clinical scientists organised in
the respective ERNs. Solve-RD provides expertise in
genomics and other -omics data analysis, through data
scientists, molecular geneticists, and bioinformaticians.
To warrant the best exchange of expertise we have
implemented two structures: (i) Data scientists and geno-


































Working Group Use Case
Cohorts
Fig. 2 The Solve-RD data analysis structure ‘in action’. Consisting
of the Data Analysis Task Force (DATF) and four Data Interpretation
Task Forces (DITF)—one per core ERN involved. The DATF
established working groups (WGs) for specific analyses. Working
groups and DITFs jointly work on analysis projects based on use cases
described by the DITF members.
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(DATF), (ii) Expert clinicians and geneticists from each
ERN are organised in a Data Interpretation Task Force
(DITF) (Fig. 2). The tasks for these structures are in brief:
►DITF: define needs of ERN for (a) data re-analysis and
(b) novel -omics data; define use cases for re-analysis and
novel analysis; discuss/test suitable data output formats for
clinical scientists; coordinate collaborative data interpreta-
tion; discuss within respective ERN network and feedback
to DATF. ►DATF: map expertise in Solve-RD and all
(ERN-)partners; create Analysis Projects (Supplementary
Table S1) based on ERNs needs; develop state-of-the-art
analysis tools; analyse data: (a) data re-analysis and (b)
novel omics data; optimise data sharing and output formats
for DITF/ERNs.
The structure implemented for data re-analysis has pro-
ven efficient and versatile [13], and will therefore be applied
for novel omics data analysis, with additional working
groups for specific -omics technologies (Fig. 3).
To integrate expertise not available within the Solve-RD
consortium, particularly with regards to molecular and
functional validation of newly found genes, Solve-RD is
implementing an innovative brokerage system (Rare Dis-
ease Models and Mechanisms Network—Europe (RDMM-
Europe)) that has already been successfully used in Canada
[14]. As of 4 December 2020, 14 “brokering” Seeding
Grants have been awarded to external model investigators.
Achievements and challenges
The work of the first 3 years of Solve-RD resulted in a
practical solution to share and jointly analyse 8393 datasets
from all over Europe: Solve-RD organised RD expertise via
a DITF and DATF with the respective working group
structure described above. The first re-analysis approaches
resulted in 255 newly diagnosed cases, mainly by lever-
aging latest ClinVar entries. As examples we refer to
adjacent articles, published jointly in this issue [13, 15–18].
Many more candidate variants and new analysis results are
under evaluation.
To achieve its current status Solve-RD has successfully
addressed some critical challenges that are (a) European
data sharing in accordance with GDPR, (b) heterogeneity in
existing WES data (e.g. 26 WES kits so far; multiple
sequencing platforms), (c) implementing a centralised ana-
lysis approach and (d) addressing the rarity of events.
It is the vision of Solve-RD that, by the end of the
project, the Solve-RD dataset will be the largest well-
annotated, standardised, multi-omics RD dataset on the
diseases covered by the four core ERNs. In this sense, we
hope that the Solve-RD dataset will be as useful to the RD
community as the gnomAD consortium is for the genomics
community [19], by making -omics data of RD populations
available to the community.
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Fig. 3 Organisation of new result flow in Solve-RD. Working
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priate). RD-REAL refers to Rare Disease - REAnalysis Logistics.
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